Sapanisertib plus Fulvestrant in Postmenopausal Women with Estrogen Receptor-Positive/HER2-Negative Advanced Breast Cancer after Progression on Aromatase Inhibitor.

José Angel García-SaenzNoelia Martínez-JáñezRicardo CubedoYolanda JerezAinhara LahuertaSantiago González-SantiagoNieves FerrerManuel Ramos Vázquez José Luis Alonso RomeroAntonio AntónEva CarrascoJingjing ChenRachel NeuwirthKevin J Galinsky Sylvie VincentE Jane LeonardDennis Slamon

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)

Fulvestrant plus sapanisertib daily/weekly resulted in numerically longer PFS in patients with ER+/HER2- advanced or metastatic breast cancer, compared with single-agent fulvestrant. The combination was associated with increased toxicity. Further development of sapanisertib using these dosing schedules in this setting is not supported by these data.

Keyphrases

metastatic breast cancer
estrogen receptor
oxidative stress
electronic health record
physical activity
bone mineral density
big data
breast cancer risk
machine learning
young adults
postmenopausal women